Dissociation of the respiratory syncytial virus F protein-specific human IgG, IgA and IgM response.
Ontology highlight
ABSTRACT: Human respiratory syncytial virus (RSV) is one of the most important causes of severe respiratory tract infections in early childhood. The only prophylactic protection is the neutralizing antibody, palivizumab, which targets a conformational epitope of the RSV fusion (F) protein. The F protein is generated as a F0 precursor containing two furin cleavage sites allowing excision of the P27 fragment and then gives rise to a fusion-competent version consisting of the N-terminal F2 subunit and the a C-terminal F1 subunits linked by two disulphide bonds. To investigate natural human F-specific antibody responses, F2 conferring the species-specificity of RSV, was expressed in Escherichia coli. Furthermore, the F0 protein, comprising both subunits F2 and F1, was expressed as palivizumab-reactive g
SUBMITTER: Borochova K
PROVIDER: S-EPMC7878790 | biostudies-literature | 2021 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA